Sphere Fluidics develops and commercialises single-cell analysis systems underpinned by its proprietary picodroplet technology, centered on the Cyto-Mine® Single Cell Analysis System. Cyto-Mine is an automated, cost-effective platform that integrates single-cell screening, sorting, dispensing, imaging, and clone verification and can process millions of samples per day. The platform is used across antibody discovery, cell line development, and single-cell diagnostics and has been purchased by global pharmaceutical companies, biotech firms, CDMOs, and leading research institutions. The company plans to use new funding to expand international sales activities and improve customer support. It will also expand product R&D programs and pursue novel applications in areas such as cell therapy, synthetic biology, and genome editing, alongside ongoing platform enhancements. As part of the announced financing, new investors will join the company board to support growth and commercialization efforts. Sphere Fluidics commercializes single-cell analysis systems underpinned by its patented picodroplet technology. Its Cyto-Mine® Single Cell Analysis System integrates single cell screening, sorting, dispensing, imaging and clone verification to streamline biologics discovery and cell line development. The platform can process up to 40 million cells per day and isolates cells producing specific antibodies or biologics. The company closed an additional $2.9 million tranche, securing a total of $4.8 million (£3.7 million) in investment, to be used as working capital for Cyto-Mine® and for expansion. Proceeds will support expansion of the UK facility, the opening of a US sales office and demo lab in California, and the doubling of personnel. Sphere Fluidics is recruiting and evaluating prospective new facilities to support the growth of its commercial and scientific activities. Sphere Fluidics develops and commercializes the Cyto‑Mine automated single‑cell analysis platform, which integrates screening, sorting, dispensing, imaging and clone verification. Cyto‑Mine can process up to 40 million cells per day and is used to streamline antibody discovery and cell line development workflows. The company is based in Cambridge, England, and sells its systems to researchers in biotherapeutic discovery and cell line development. Sphere Fluidics closed a $2 million (circa £1.5 million) investment round to accelerate growth in operations and support sales of Cyto‑Mine. The funds will be used to expand operations and sales capabilities across the UK and USA and to open a new US West Coast sales office. Management said it will invest in automating and streamlining manufacturing across its product range and expects to raise additional funds to expand capabilities further. Sphere Fluidics develops Cyto-Mine, an integrated device that uses picodroplet technology and microfluidics to process around 1 million heterogeneous mammalian cells in less than half a day. Each cell is encapsulated in a picodroplet containing growth media that acts as a bioreactor, enabling compartmentalization, growth, trapping of secreted molecules such as antibodies, and selective screening to find rare lead candidates. The company is led by Dr. Frank F. Craig (CEO), Dr. Marian Rehak (R&D Director) and Dr. Rob Marchmont (Commercial Director). Sphere Fluidics secured $7M in the first close of its latest funding round, which remains open. The company intends to use the proceeds to accelerate development of the manufactured version of Cyto-Mine and to enable a commercial launch later in the year reported. The business is based in Cambridge, UK. Sphere Fluidics develops proprietary products and collaborative R&D services for single-cell analysis and characterisation. The company was founded on IP generated by the University of Cambridge and has in‑licensed 10 patent families from the University and other institutions. Its core technology is protected by 51 patents. Development to date has been funded with £2.3m of equity and over £7m of grants. The articles position the company as an established life sciences business with a protected technology base and ongoing external investment activity. No operating metrics (revenue/users) are provided in the articles.

Total raised

$59M

Funding rounds

7

Latest round

Equity

Latest activity

Oct 2021